ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: Implication of their dopamine-modulatory actions

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Mizuno, M ^a,b   Sotoyama, H ^a   Namba, H ^a   Shibuya, M ^a   Eda, T ^a   Wang, R ^a   Okubo, T ^a   Nagata, K ^b   Iwakura, Y ^a   Nawa, H ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b INSTITUTE FOR DEVELOPMENTAL RESEARCH   (Japan)

Author keywords

dopamine; EGF; ErbB; globus pallidus; schizophrenia

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; DOPAMINE; GEFITINIB; HALOPERIDOL; RISPERIDONE; 4 ((3 BROMOPHENYL)AMINO) 6,7 DIMETHOXYQUINAZOLINE; 4-((3-BROMOPHENYL)AMINO)-6,7-DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NEUROLEPTIC AGENT; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG POTENCY; FEAR; LOCOMOTION; MALE; NONHUMAN; PREPULSE INHIBITION; RAT; SCHIZOPHRENIA; STARTLE REFLEX; WEIGHT GAIN; ANIMAL; BRAIN LEVEL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; MOTOR ACTIVITY; PSYCHOLOGY; SPRAGUE DAWLEY RAT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; FEMALE; MALE; MOTOR ACTIVITY; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STARTLE REACTION; REFLEX, STARTLE;

EID: 84878634565     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.29     Document Type: Article

References (57)

1. Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, Tsuchiya K et al. Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry 2002; 7: 673-682. (Pubitemid 34984943)
2. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71: 877-892. (Pubitemid 135750519)
3. Seroogy KB, Numan S, Gall CM, Lee DC, Kornblum HI. Expression of EGF receptor mRNA in rat nigrostriatal system. Neuroreport 1994; 6: 105-108.
4. Steiner H, Blum M, Kitai ST, Fedi P. Differential expression of ErbB3 and ErbB4 neuregulin receptors in dopamine neurons and forebrain areas of the adult rat. Exp Neurol 1999; 159: 494-503. (Pubitemid 29485235)
5. Abe Y, Namba H, Zheng Y, Nawa H. In situ hybridization reveals developmental regulation of ErbB1-4 mRNA expression in mouse midbrain: implication of ErbB receptors for dopaminergic neurons. Neuroscience 2009; 161: 95-110.
6. Futamura T, Kakita A, Tohmi M, Sotoyama H, Takahashi H, Nawa H. Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: implication for epidermal growth factor in cognitive development. Mol Psychiatry 2003; 8: 19-29. (Pubitemid 36188570)
7. Yurek DM, Zhang L, Fletcher-Turner A, Seroogy KB. Supranigral injection of neuregulin1- beta induces striatal dopamine overflow. Brain Res 2004; 1028: 116-119. (Pubitemid 39424185)
8. Mizuno M, Sotoyama H, Narita E, Kawamura H, Namba H, Zheng Y et al. A cyclooxygenase-2 inhibitor ameliorates behavioral impairments induced by striatal administration of epidermal growth factor. J Neurosci 2007; 27: 10116-10127. (Pubitemid 47450461)
9. Zhang L, Fletcher-Turner A, Marchionni MA, Apparsundaram S, Lundgren KH, Yurek DM et al. Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures. J Neurochem 2004; 91: 1358-1368. (Pubitemid 39658562)
10. Iwakura Y, Zheng Y, Sibilia M, Abe Y, Piao YS, Yokomaku D et al. Qualitative and quantitative re-evaluation of epidermal growth factor-ErbB1 action on developing midbrain dopaminergic neurons in vivo and in vitro: target-derived neurotrophic signaling (Part 1): J Neurochem 2011; 118: 45-56.
11. Carlsson T, Schindler FR, Hollerhage M, Depboylu C, Arias-Carrio'n O, Schnurrbusch S et al. Systemic administration of neuregulin-1b1 protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem 2011; 117: 1066-1074.
12. Kwon OB, Paredes D, Gonzalez CM, Neddens J, Hernandez L, Vullhorst D et al. Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. Proc Natl Acad Sci USA 2008; 105: 15587-15592.
13. Tomiyama K, O'Tuathaigh CM, O'Sullivan GJ, Kinsella A, Lai D, Harvey RP et al. Phenotype of spontaneous orofacial dyskinesia in neuregulin-1 'knockout' mice. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 330-333.
14. Kato T, Kasai A, Mizuno M, Fengyi L, Shintani N, Maeda S et al. Phenotypic characterization of transgenic mice overexpressing neuregulin-1. PLoS ONE 2010; 5: e14185.
15. Kato T, Abe Y, Sotoyama H, Kakita A, Kominami R, Hirokawa S et al. Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol Psy 2011; 16: 307-320.
16. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006; 60: 132-140.
17. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008; 9: 437-452. (Pubitemid 351704944)
18. Nawa H, Takei N. Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 2006; 56: 2-13. (Pubitemid 44376487)
19. Pereira A, Sugiharto-Winarno A, Zhang B, Malcolm P, Fink G, Sundram S. Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs. Int J Neuropsychopharmacol 2012; 15: 1149-1160.
20. Iwakura Y, Wang R, Abe Y, Piao YS, Shishido Y, Higashiyama S et al. Dopaminedependent ectodomain shedding and release of epidermal growth factor in developing striatum: target-derived neurotrophic signaling (Part 2): J Neurochem 2011; 18: 57-68.
21. Iwakura Y, Piao YS, Mizuno M, Takei N, Kakita A, Takahashi H et al. Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons. J Neurochem 2005; 93: 974-983. (Pubitemid 40695756)
22. Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R. The involvement of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 142-148. (Pubitemid 43214789)
23. Iwakura Y, Nawa H. ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease. Front Cell Neurosci 2013; 7: 4.
24. Mizuno M, Iwakura Y, Shibuya M, Zheng Y, Eda T, Kato T et al. Antipsychotic potential of quinazoline ErbB1 inhibitors in a schizophrenia model established with neonatal hippocampal lesioning. J Pharmacol Sci 2010; 114: 320-331.
25. Nawa H, Mizuno M. Antipsychotic molecular-targeting epithelial growth factor receptor. United States Patent Application 20060167026.
26. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM. Longterm behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 2001; 107: 535-550. (Pubitemid 33097492)
27. Tohmi M, Tsuda N, Mizuno M, Takei N, Frankland PW, Nawa H. Distinct influences of neonatal epidermal growth factor challenge on adult neurobehavioral traits in four mouse strains. Behav Genet 2005; 35: 615-629. (Pubitemid 41355979)
28. Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HD et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3- bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 1996; 39: 267-276.
29. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61: 8887-8895. (Pubitemid 34013905)
30. Park GT, Kim HY, Kim EK, Yang JM. Autocrine extracellular signal-regulated kinase activation in normal human keratinocytes is not interrupted by calcium triggering and is involved in the control of cell cycle at the early stage of calcium-induced differentiation. J Korean Med Sci 2007; 22: 290-297.
31. Takei N, Kawamura M, Ishizuka Y, Kakiya N, Inamura N, Namba H et al. Brain-derived neurotrophic factor enhances the basal rate of protein synthesis by increasing active eukaryotic elongation factor 2 levels and promoting translation elongation in cortical neurons. J Biol Chem 2009; 284: 26340-26348.
32. Swerdlow NR, Braff DL, Geyer MA. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 2000; 11: 185-204. (Pubitemid 30449750)
33. Zhang WN, Murphy CA, Feldon J. Behavioural and cardiovascular responses during latent inhibition of conditioned fear: measurement by telemetry and conditioned freezing. Behav Brain Res 2004; 154: 199-209. (Pubitemid 39070468)
34. Mameli-Engvall M, Evrard A, Pons S, Maskos U, Svensson TH, Changeux JP et al. Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors. Neuron 2006; 50: 911-921. (Pubitemid 43850688)
35. Ungless MA, Grace AA. Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons. Trends Neurosci 2012; 35: 422-430.
36. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 1984; 4: 2877-2890. (Pubitemid 15224432)
37. Tsuda N, Mizuno M, Yamanaka T, Komurasaki T, Yoshimoto M, Nawa H. Common behavioral influences of the ErbB1 ligands transforming growth factor alpha and epiregulin administered to mouse neonates. Brain Dev 2008; 30: 533-543.
38. Mizuno M, Malta RS Jr, Nagano T, Nawa H. Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period. Ann NY Acad Sci 2004; 1025: 612-618. (Pubitemid 39643915)
39. Mizuno M, Kawamura H, Takei N, Nawa H. The anthraquinone derivative emodin ameliorates neurobehavioral deficits of a rodent model for schizophrenia. J Neural Transm 2008; 115: 521-530.
40. Fry DW. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des 2000; 15: 3-16. (Pubitemid 30364895)
41. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003; 4: 397-406. (Pubitemid 36833681)
42. McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 2005; 4: 641-649. (Pubitemid 40601846)
43. Sotoyama H, Zheng Y, Iwakura Y, Mizuno M, Aizawa M, Shcherbakova K et al. Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF. PLoS ONE 2011; 6: e25831.
44. Weiner I, Arad M. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav Brain Res 2009; 204: 369-386.
45. Kodsi MH, Swerdlow NR. Prepulse inhibition in the rat is regulated by ventral and caudodorsal striato-pallidal circuitry. Behav Neurosci 1995; 109: 912-928.
46. Sotoyama H, Namba H, Takei N, Nawa H. Neonatal exposure to epidermal growth factor induces dopamine D2-like receptor supersensitivity in adult sensorimotor gating. Psychopharmacology (Berl) 2007; 191: 783-792. (Pubitemid 46355897)
47. Arai S, Takuma K, Mizoguchi H, Ibi D, Nagai T, Takahashi K et al. Involvement of pallidotegmental neurons in methamphetamine-and MK-801-induced impairment of prepulse inhibition of the acoustic startle reflex in mice: reversal by GABAB receptor agonist baclofen. Neuropsychopharmacology 2008; 33: 3164-3175.
48. Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci 2007; 8: 221-232. (Pubitemid 46294661)
49. Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron 2006; 52: 179-196. (Pubitemid 44466363)
50. Meyer U, Feldon J. Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl) 2009; 206: 587-602.
51. Sotoyama H, Namba H, Chiken S, Nambu A, Nawa H. Abnormal hyperactivity of pallidal GABA neurons in the schizophrenia animal model established by the cytokine EGF exposure. J Neurochem 2013; doi:10.1111/jnc.12223.
52. Morrison PD, Murray RM. From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophr Bull 2009; 35: 668-674.
53. Pan B, Huang XF, Deng C. Antipsychotic treatment and neuregulin-1-ErbB4 signalling in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatr 2011; 35: 924-930.
54. Wang XD, Su YA, Guo CM, Yang Y, Si TM. Chronic antipsychotic drug administration alters the expression of neuregulin 1b, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. Int J Neuropsychopharmacol 2008; 11: 553-556.
55. Pan B, Huang XF, Hu CH, Han M, Deng C. Effects of typical and atypical antipsychotics on the expressions of neuregulin 1 and ErbB4 receptors. Aust New Zealand J Psychiatry 2010; 44(Suppl.1): A49.
56. Pereira A, Fink G, Sundram S. Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor. J Mol Neurosci 2009; 39: 185-198.
57. Melamed E, Durst R, Frucht Y, Globus M. Differential effect of acute and chronic haloperidol administration on dopamine turnover in rat nigrostriatal and retinal dopaminergic neurons. Eur J Pharmacol 1983; 89: 279-282. (Pubitemid 13095871)